The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 101–200 of 998
Fujimoto, A., Fujita, M., Hasegawa, T., Wong, J. H., Maejima, K., Oku‐Sasaki, A., Nakano, K., Shiraishi, Y., Miyano, S., Imoto, S., et al. (2020) · Genome Research · doi:10.1101/gr.255026.119 · Cited by 84
“3 Introduction Recent large-scale whole genome sequencing studies have revealed the complexity of the mutational landscape of the cancer genome (1-4).”
BackgroundMethodGWAS in cancer: progress and challenges
Liang, B., Ding, H., Huang, L., Luo, H., & Zhu, X. M. (2020) · Molecular Genetics and Genomics · doi:10.1007/s00438-020-01647-z · Cited by 82
Hofman, D. A., Ruiz‐Orera, J., Yannuzzi, I., Murugesan, R. A., Brown, A., Clauser, K. R., Condurat, A. L., van Dinter, J. T., Engels, S. A. G., Goodale, A. B., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2023.12.003 · Cited by 94
Lafay-Cousin, L., Bouffet, E., Strother, D., Rudneva, V., Hawkins, C., Eberhart, C., Horbinski, C., Heier, L., Souweidane, M., Williams-Hughes, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00845 · Cited by 77
“All next-generation sequencing data were harmonized and processed with the same analysis pipelines to ensure consistent germline and somatic mutation calling.(11) All mutations and copy number variation calls were manually curated by inspecting sequence alignments and genome-wide copy number plots.”
MethodSelf-citationEpigenetic Drivers in Pediatric Medulloblastoma
Roussel, M. F., & Stripay, J. L. (2017) · The Cerebellum · doi:10.1007/s12311-017-0899-9 · Cited by 90
Huang, M., Tailor, J. K., Zhen, Q., Gillmor, A. H., Miller, M. L., Weishaupt, H., Chen, J., Zheng, T., Nash, E. K., McHenry, L. K., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.05.013 · Cited by 83
“Mutation of PTCH1 occurs frequently in SHH medulloblastoma (Cavalli et al., 2017; Kool et al., 2014; Northcott et al., 2017), and Ptch1 +/− drives medulloblastoma in mice (Goodrich et al., 1997).”
InfluentialSelf-citationDeconstructing Sonic Hedgehog Medulloblastoma: Molecular Subtypes, Drivers, and Beyond
García-López, J., Kumar, R., Smith, K. S., & Northcott, P. A. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.11.001 · Cited by 82
Self-citationIorgulescu, J. B., Sun, C., Neff, C., Cioffi, G., Gutierrez, C., Kruchko, C. A., Ruhl, J., Waite, K. A., Negoita, S., Hofferkamp, J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac113 · Cited by 75
Self-citationAn update on the central nervous system manifestations of Li–Fraumeni syndrome
Orr, B. A., Clay, M. R., Pinto, E. M., & Kesserwan, C. A. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02055-3 · Cited by 87
“Only very rarely are TP53 mutations found in group 3 or group 4 tumors [74, 81, 84, 89].”
BackgroundZika Virus Selectively Kills Aggressive Human Embryonal CNS Tumor Cells In Vitro and In Vivo
Kaid, C., Goulart, E., de Caires-Junior, L. C., Araújo, B. H. S., Schanoski, A. S., Bueno, H. M. S., Telles-Silva, K. A., Astray, R. M., Assoni, A. F., Júnior, A. F. R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3201 · Cited by 88
“Translating these results to the clinical setting, patients with aggressive AT/RT and medulloblastoma should be good candidates for a future oncolytic therapy with ZIKV, because Wnt pathway activation plays an important role in the biology of both tumor types (27, 30), contributing to stemness and therapeutic resistan…”
MethodDunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad031 · Cited by 73
“28,29 c .”
Self-citationMedulloblastoma: optimizing care with a multidisciplinary approach
Thomas, A., & Noël, G. (2019) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s167808 · Cited by 83
Medulloblastoma genomics in the modern molecular era
Kumar, R., Liu, A. P. Y., & Northcott, P. A. (2019) · Brain Pathology · doi:10.1111/bpa.12804 · Cited by 85
“In addition to WNT tumors, DDX3X is also mutated in SHH MBs, albeit at a slightly lower frequency of about 20% (63).”
BackgroundInfluentialSelf-citationA Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules
Patel-Murray, N. L., Adam, M., Huynh, N. C., Wassie, B. T., Milani, P., & Fraenkel, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-57691-7 · Cited by 81
Self-citationSubgroup and subtype-specific outcomes in adult medulloblastoma
Coltin, H., Sundaresan, L., Smith, K. S., Skowron, P., Massimi, L., Eberhart, C. G., Schreck, K. C., Gupta, N. M., Weiss, W. A., Tirapelli, D. P. D. C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02358-4 · Cited by 79
Self-citationCircular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma
Chapman, O. S., Luebeck, J., Sridhar, S., Wong, I. T.-L., Dixit, D., Wang, S., Prasad, G., Rajkumar, U., Pagadala, M. S., Larson, J. D., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01551-3 · Cited by 90
“Where available, patient samples and models were assigned metadata annotations including age, sex, survival and medulloblastoma sub-group based on previously published annotations of the same tumor or model 18,23,31,37,69–71 .”
BackgroundMethodInfluentialSelf-citationGarancher, A., Lin, C. Y., Morabito, M., Richer, W., Rocques, N., Larcher, M., Bihannic, L., Smith, K., Miquel, C., Leboucher, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.006 · Cited by 73
Self-citationMultifaceted Role of PRDM Proteins in Human Cancer
Casamassimi, A., Rienzo, M., Zazzo, E. D., Sorrentino, A., Fiore, D., Proto, M., Moncharmont, B., Gazzerro, P., Bifulco, M., & Abbondanza, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072648 · Cited by 84
“Interestingly, many “enhancer hijacking” events activating PRDM6 were observed in a medulloblastoma molecular subtype [146].”
BackgroundKumar, R., Liu, A. P. Y., Orr, B. A., Northcott, P. A., & Robinson, G. W. (2018) · Cancer · doi:10.1002/cncr.31583 · Cited by 74
Self-citationSokolov, D., Sharda, N., Banerjee, A., Denisenko, K., Basalious, E. B., Shukla, H. D., Waddell, J., Hamdy, N. Μ., & Banerjee, A. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128277350231219062154 · Cited by 78
Lee, J. C., Mazor, T., Lao, R., Wan, E., Diallo, A. B., Hill, N. S., Thangaraj, N., Wendelsdorf, K., Samuel, D., Kline, C. N., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01990-5 · Cited by 71
Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource
Smith, K. S., Xu, K., Mercer, K., Boop, F. A., Klimo, P., DeCupyere, M., Grenet, J. A., Robinson, S., Dunphy, P. S., Baker, S. J., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02171-5 · Cited by 77
Self-citationMedulloblastoma: Current Perspectives and Recent Advances
Choi, J. Y. (2023) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2022.0046 · Cited by 89
“It shows mutations or copy number alterations of genes related to the SHH signaling pathway [19].”
BackgroundInfluentialCharacterizing temporal genomic heterogeneity in pediatric high-grade gliomas
Salloum, R., McConechy, M. K., Mikael, L. G., Fuller, C. E., Drissi, R., DeWire, M. D., Nikbakht, H., Jay, N. D., Yang, X., Boué, D. R., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0479-8 · Cited by 74
Self-citationA review of dynamical systems approaches for the detection of chaotic attractors in cancer networks
Uthamacumaran, A. (2021) · Patterns · doi:10.1016/j.patter.2021.100226 · Cited by 77
“Similar phenotypic clustering by molecular profiling have been paved for MB. 59,60 Four major distinct molecular subtypes of MB, namely WNT, Shh, group 3 and group 4, exhibit distinctive transcriptional and epigenetic signatures that define clinically observed patient subsets.”
BackgroundOpenPBTA: The Open Pediatric Brain Tumor Atlas
Shapiro, J. A., Gaonkar, K. S., Spielman, S. J., Savonen, C., Bethell, C. J., Jin, R., Rathi, K. S., Zhu, Y., Egolf, L. E., Farrow, B., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100340 · Cited by 87
A survey and evaluation of Web-based tools/databases for variant analysis of TCGA data
Zhang, Z., Li, H., Jiang, S., Li, R., Li, W., Chen, H., & Bo, X. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby023 · Cited by 86
Genetic Predisposition to Solid Pediatric Cancers
Capasso, M., Montella, A., Tirelli, M., Maiorino, T., Cantalupo, S., & Iolascon, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590033 · Cited by 74
“MBWNT is characterized at somatic level by activating mutations in exon 3 of β-catenin (CTNNB1) andmonosomy of chromosome 6, while MBSHH by amplification of GLI2 andMYCN, as well as loss of 17p (16).”
BackgroundInfluentialTargeting oncogenic Notch signaling with SERCA inhibitors
Pagliaro, L., Marchesini, M., & Roti, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01015-9 · Cited by 70
The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications
Xu, Y., & Ruggero, D. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033420 · Cited by 67
“Specifically, the eIF3h subunit is amplified in breast cancer and malignant prostate cancer (Nupponen et al. 1999, Saramaki et al. 2001), whereas the expressions of other subunits, such as eIF3e and eIF3f, are downregulated in various cancers (Marchetti et al. 2001, Shi et al. 2006).”
BackgroundWeishaupt, H., Johansson, P., Sundström, A., Lubovac-Pilav, Z., Olsson, B. E., Nelander, S., & Swartling, F. J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz066 · Cited by 75
Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma
Begemann, M., Waszak, S. M., Robinson, G. W., Jäger, N., Sharma, T., Knopp, C., Kraft, F., Moser, O., Mynarek, M., Guerrini‐Rousseau, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00577 · Cited by 73
Self-citationOoi, C. Y., Carter, D. R., Liu, B., Mayoh, C., Beckers, A., Lalwani, A., Nagy, Z. S., Brouwer, S. D., Decaesteker, B., Hung, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3034 · Cited by 66
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
5-ALA fluorescence–guided surgery in pediatric brain tumors—a systematic review
Schwake, M., Schipmann, S., Müther, M., Köchling, M., Brentrup, A., & Stummer, W. (2019) · Acta Neurochirurgica · doi:10.1007/s00701-019-03898-1 · Cited by 71
The duality of PRDM proteins: epigenetic and structural perspectives
Tullio, F. D., Schwarz, M. C., Zorgati, H., Mzoughi, S., & Guccione, E. (2021) · FEBS Journal · doi:10.1111/febs.15844 · Cited by 84
SGL-SVM: A novel method for tumor classification via support vector machine with sparse group Lasso
Huo, Y., Xin, L., Kang, C., Wang, M., Ma, Q., & Yu, B. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110098 · Cited by 73
Menyhárt, O., Giangaspero, F., & Győrffy, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0712-y · Cited by 80
Lucas, C.-H. G., Gupta, R. K., Doo, P., Lee, J. C., Cadwell, C. R., Ramani, B., Hofmann, J. W., Sloan, E. A., Kleinschmidt-DeMasters, B. K., Lee, H. S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01027-z · Cited by 64
Langenberg, K. P. S., Meister, M. T., Bakhuizen, J. J., Boer, J. M., van Eijkelenburg, N. K. A., Hulleman, E., Ilan, U., Looze, E. J., Dierselhuis, M. P., van der Lugt, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.09.001 · Cited by 77
Self-citationctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer
Escudero, L., Ricarte, F. M., & Seoane, J. (2021) · Cancers · doi:10.3390/cancers13091989 · Cited by 66
Lee, B., Mahmud, I., Pokhrel, R., Murad, R., Yuan, M., Stapleton, S. L., Bettegowda, C., Jallo, G. I., Eberhart, C. G., Garrett, T. J., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01326-7 · Cited by 73
“More recent studies with increased cohort sizes have identified intra-subtypes and described a total of twelve subgroups [7, 8].”
BackgroundThe SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Lospinoso Severini, L., Ghirga, F., Bufalieri, F., Quaglio, D., Infante, P., & Di Marcotullio, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1823967 · Cited by 61
Marquardt, V., Theruvath, J. L., Pauck, D., Picard, D. J., Qin, N., Blümel, L., Maue, M., Bartl, J., Ahmadov, U., Langini, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005871 · Cited by 67
Self-citationReuter, M. S., Walker, S., Thiruvahindrapuram, B., Whitney, J., Cohn, I., Sondheimer, N., Yuen, R. K. C., Trost, B., Paton, T. A., Pereira, S. L., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.171151 · Cited by 61
Shimada, I. S., Hwang, S.-H., Somatilaka, B. N., Wang, X., Skowron, P., Kim, J., Kim, M., Shelton, J. M., Rajaram, V., Xuan, Z., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.018 · Cited by 52
“In addition, we did not detect any homozygous deletions in the Gpr161 locus in 827 patients tested (Northcott et al., 2017), implying that this locus is not a common hotspot for tumor initiation in patients.”
BackgroundSelf-citationMolecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
Wong, Q. H., Li, K. K., Wang, W., Malta, T. M., Noushmehr, H., Grabovska, Y., Jones, C., Chan, A. K., Kwan, J. S. H., Huang, Q. J., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00778-x · Cited by 64
Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers
Khater, F., Vairy, S., Langlois, S., Dumoucel, S., Sontag, T., St-Onge, P., Bittencourt, H. N. D. S., Soglio, D. B. D., Champagne, J., Duval, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2906 · Cited by 70
Self-citationČančer, M., Hutter, S., Holmberg, K. O., Rosén, G., Sundström, A., Tailor, J. K., Bergström, T., Garancher, A., Essand, M., Wechsler‐Reya, R. J., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.10.005 · Cited by 63
“However, there are strikingly few reported mutations in pluripotency factors or stemness genes in tumor biopsies from SHH MB patients (Northcott et al., 2017).”
BackgroundInfluentialReduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma
Ecker, J., Thatikonda, V., Sigismondo, G., Selt, F., Valinciute, G., Oehme, I., Müller, C., Buhl, J. L., Ridinger, J., Usta, D., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa191 · Cited by 60
Self-citationThe genetic landscape of choroid plexus tumors in children and adults
Thomas, C., Soschinski, P., Zwaig, M., Oikonomopoulos, S., Okonechnikov, K., Pajtler, K. W., Sill, M., Schweizer, L., Koch, A., Neumann, J. E., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa267 · Cited by 60
Self-citationZhao, L., Wang, W., Xu, L., Yi, T., Zhao, X., Wei, Y., Vermeulen, L., Goel, A., Zhou, S., & Wang, X. (2018) · Oncogene · doi:10.1038/s41388-018-0577-5 · Cited by 64
Rapid discrimination of pediatric brain tumors by mass spectrometry imaging
Clark, A. R., Calligaris, D., Regan, M. S., Pomeranz Krummel, D., Agar, J. N., Kallay, L., MacDonald, T., Schniederjan, M., Santagata, S., Pomeroy, S. L., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2978-2 · Cited by 57
Self-citationNotch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma
Kahn, S. A., Wang, X., Nitta, R. T., Gholamin, S., Theruvath, J. L., Hütter, G., Azad, T. D., Wadi, L., Bolin, S., Ramaswamy, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06564-9 · Cited by 65
Self-citationSubgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma
Park, A. K., Lee, J. Y., Cheong, H., Ramaswamy, V., Park, S., Kool, M., Phi, J. H., Choi, S. A., Cavalli, F. M. G., Taylor, M. D., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5742-x · Cited by 73
Self-citationSuwala, A. K., Stichel, D., Schrimpf, D., Maas, S. L. N., Sill, M., Dohmen, H., Banan, R., Reinhardt, A., Sievers, P., Hinz, F. E., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02302-6 · Cited by 62
Self-citationChildhood Malignant Brain Tumors: Balancing the Bench and Bedside
Thorbinson, C., & Kilday, J. (2021) · Cancers · doi:10.3390/cancers13236099 · Cited by 68
“Mutations in the adenomatous polyposis coli (APC) gene are common in WNT tumors lacking CTTNB1 mutations [15,24].”
BackgroundResultInfluentialPan-3D genome analysis reveals structural and functional differentiation of soybean genomes
Ni, L., Liu, Y., Ma, X., Liu, T., Yang, X., Wang, Z., Liang, Q., Liu, S., Zhang, M., Wang, Z., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02854-8 · Cited by 64
Self-citationThe whole-genome panorama of cancer drivers
Sabarinathan, R., Pich, O., Martincorena, I., Rubio-Perez, C., Juul, M., Wala, J., Schumacher, S., Shapira, O., Sidiropoulos, N., Waszak, S. M., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/190330 · Cited by 54
“APC Coding muts (43) CNA loss (13) Intron splicing (3) Germline (1) Biallelic loss (12) TP53 Coding muts (30) CNA loss (25) Biallelic loss (25)”
BackgroundSelf-citationCancer Predisposition Syndromes and Medulloblastoma in the Molecular Era
Carta, R., Baldo, G. D., Miele, E., Pò, A., Besharat, Z. M., Nazio, F., Colafati, G. S., Piccirilli, E., Agolini, E., Rinelli, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566822 · Cited by 65
Lazow, M., Palmer, J. D., Fouladi, M., & Salloum, R. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01273-0 · Cited by 66
Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer
Cong, G., Zhu, X., Chen, X., Chen, H., & Chong, W. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02327-w · Cited by 73
Deng, M. Y., Sturm, D., Pfaff, E., Sill, M., Stichel, D., Balasubramanian, G. P., Tippelt, S., Kramm, C. M., Donson, A. M., Green, A. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25708-y · Cited by 62
Self-citationMedulloblastoma: Molecular understanding, treatment evolution, and new developments
Liu, X., Ding, C., Tan, W., & Zhang, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107516 · Cited by 54
Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma
Rusert, J. M., Juarez, E. F., Brabetz, S., Jensen, J., Garancher, A., Chau, L. Q., Tacheva-Grigorova, S. K., Wahab, S., Udaka, Y. T., Finlay, D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1655 · Cited by 67
Self-citationYan, J., Zhang, S., Li, K. K., Wang, W., Li, K., Duan, W., Yuan, B., Wang, L., Liu, L., Zhan, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103093 · Cited by 56
“Notable findings have been discovered in the aspects of different tumor origins [5], various genetic profiles [6], differential phenotypes [3,4], diverse clinical traits [4], distinct prognosis [3,4] and potential therapeutic responses [2] among the four subgroups.”
BackgroundClinical and mutational profiles of adult medulloblastoma groups
Wong, G. C.-H., Li, K. K., Wang, W., Liu, A. P. Y., Huang, Q. J., Chan, A. K., Poon, M. F., Chung, N. Y., Wong, Q. H., Chen, H., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01066-6 · Cited by 64
Dufour, C., Foulon, S., Geoffray, A., Masliah‐Planchon, J., Figarella‐Branger, D., Bernier, V., Padovani, L., Guerrini‐Rousseau, L., Faure‐Conter, C., Icher, C., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa301 · Cited by 55
Martirosian, V., Deshpande, K., Zhou, H., Shen, K., Smith, K. S., Northcott, P. A., Lin, M. P., Stepanosyan, V., Das, D., Remšík, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109302 · Cited by 59
“DNA Methylation Analysis— DNA methylation sequences from 104 medulloblastoma tissues were obtained from Northcott et al. (2017) from their published data.”
Self-citationEssential Management of Pediatric Brain Tumors
Lutz, K., Jünger, S. T., & Messing‐Jünger, M. (2022) · Children · doi:10.3390/children9040498 · Cited by 72
“New diagnostic technologies, such as NGS and DNA methylome profiling, have resulted in a new tumor classification of medulloblastomas [7,73,76], according to the concept that an analogous molecular transcriptome corresponds to similar tumor behavior [75,76].”
Zhang, S., Pei, Z., Lei, C., Zhu, S., Deng, K., Zhou, J., Yang, H. J., Lu, D., Sun, X., Xu, C., et al. (2022) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2022-108553 · Cited by 57
Woolman, M., Kuzan-Fischer, C. M., Ferry, I., Kiyota, T., Luu, B., Wu, M., Muñoz, D. G., Das, S., Aman, A. M., Taylor, M. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3411 · Cited by 57
Self-citationRivero-Hinojosa, S., Grant, M., Panigrahi, A. K., Zhang, H., Caisová, V., Bollard, C. M., & Rood, B. R. (2021) · Nature Communications · doi:10.1038/s41467-021-26936-y · Cited by 72
Mechanosensitive brain tumor cells construct blood-tumor barrier to mask chemosensitivity
Chen, X., Momin, A., Wanggou, S., Wang, X., Min, H.-K., Dou, W., Gong, Z., Chan, J., Dong, W., Fan, J. J., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.007 · Cited by 55
Self-citationRETRACTED ARTICLE: Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis
Luo, Z., Xia, M., Shi, W., Zhao, C., Wang, J., Xin, D. E., Dong, X., Xiong, Y., Zhang, F., Berry, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05487-2 · Cited by 64
“G3 and G4 MBs share similar signature genes based on bulk transcriptome and DNA methylation profiles 4,27 .”
Self-citationRetractedProteomic analysis of Medulloblastoma reveals functional biology with translational potential
Rivero-Hinojosa, S., Lau, L. S., Stampar, M., Staal, J., Zhang, H., Gordish-Dressman, H., Northcott, P. A., Pfister, S. M., Taylor, M. D., Brown, K. J., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0548-7 · Cited by 52
“But the other two subgroups, 3 and 4, do not harbor mutations at the same frequency and present a greater challenge when trying to discern their biological determinants from gene expression signatures alone [48].”
BackgroundSelf-citationMYC Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells
Tao, R., Murad, N., Xu, Z., Zhang, P., Okonechnikov, K., Kool, M., Rivero-Hinojosa, S., Lazarski, C. A., Zheng, P., Liu, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1787 · Cited by 72
“To determine whether these tumors resemble Group 3 medulloblastoma at the molecular level, we performed RNA-Seq analysis on mouse MYC-driven tumors and compared the gene expression profiles with those of 167 human tumor samples from a recent global medulloblastoma study [2].”
BackgroundResultInfluentialSelf-citationEffects of Radiation Therapy on Neural Stem Cells
Michaelidesova, A. J., Konířová, J., Bartůněk, P., & Zíková, M. (2019) · Genes · doi:10.3390/genes10090640 · Cited by 60
“For instance, medulloblastomas comprise an explicit subgroup with distinct molecular characteristics [141,142] and provide a clear example of how a detailed understanding of genomics can guide the treatment procedure.”
BackgroundModeling pediatric medulloblastoma
Roussel, M. F., & Stripay, J. L. (2019) · Brain Pathology · doi:10.1111/bpa.12803 · Cited by 55
“Recently, each of the four groups has been further subdivided into subgroups by methylation profiling (14, 52).”
BackgroundThe molecular biology of medulloblastoma metastasis
Ommeren, R. V., Garzia, L., Holgado, B., Ramaswamy, V., & Taylor, M. D. (2020) · Brain Pathology · doi:10.1111/bpa.12811 · Cited by 62
Self-citationVenkataramany, A. S., Schieffer, K. M., Lee, K., Cottrell, C. E., Wang, P. Y., Mardis, E. R., Cripe, T. P., & Chandler, D. S. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.03.011 · Cited by 58
Recent Advances in Pediatric Medulloblastoma
Jackson, K., & Packer, R. J. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01316-9 · Cited by 63
Developmental origins and oncogenic pathways in malignant brain tumors
Lu, Q. R., Qian, L., & Zhou, X. (2019) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.342 · Cited by 60
“The most frequently seen genetic alterations in G4-MB include amplification of MYCN and CDK6, mutations in KDM6A, which encodes a histone demethylase, and tandem duplication of SNCAIP, and overexpression of its downstream gene PRDM6 (Northcott et al., 2017; Pugh et al., 2012).”
BackgroundSelf-citationGenomics of adult and pediatric solid tumors.
Rahal, Z., Abdulhai, F., Kadara, H. N., & Saab, R. H. (2018) · Europe PMC (PubMed Central) · Cited by 58
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse
Richardson, S., Hill, R. M., Kui, C., Lindsey, J. C., Grabovksa, Y., Keeling, C., Pease, L. I., Bashton, M., Crosier, S., Vinci, M., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab178 · Cited by 64
Self-citationConverging mechanism of UM171 and KBTBD4 neomorphic cancer mutations
Xie, X., Zhang, O., Yeo, M. J. R., Lee, C., Tao, R., Harry, S. A., Payne, N. C., Nam, E., Paul, L., Li, Y., et al. (2025) · Nature · doi:10.1038/s41586-024-08533-3 · Cited by 50
“In the case of KBTBD4, both point substitutions and diverse indels can occur in group 3 and 4 MB, with a marked bias towards the latter 3 .”
Self-citationGruber, W., Peer, E., Elmer, D. P., Sternberg, C., Tesanovic, S., del Burgo, P. J., Coni, S., Canettieri, G., Neureiter, D., Bartz, R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31117 · Cited by 50
Beckmann, P. J., Larson, J. D., Larsson, A. T., Ostergaard, J., Wagner, S., Rahrmann, E. P., Shamsan, G. A., Otto, G. M., Williams, R. L., Wang, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1261 · Cited by 51
“Medulloblastoma includes four molecular subgroups: WNT, SHH, group 3, and group 4; WNT and SHH are associated with mutations activating those pathways, but groups 3 and 4 remain less defined(4).”
BackgroundSelf-citationSadowski, M., Kraft, A., Szałaj, P., Wlasnowolski, M., Tang, Z., Ruan, Y., & Plewczyński, D. (2019) · Genome biology · doi:10.1186/s13059-019-1728-x · Cited by 63
“Accumulation of SVs proximal to the TAD boundary occupied by CTCF was postulated to cause enhancer hijacking and PRDM6 overexpression in medulloblastoma samples [9].”
BackgroundWnt activation as a therapeutic strategy in medulloblastoma
Manoranjan, B., Venugopal, C., Bakhshinyan, D., Adile, A., Richards, L. M., Kameda-Smith, M. M., Whitley, O., Dvorkin‐Gheva, A., Subapanditha, M., Savage, N. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17953-4 · Cited by 57
Mapping pediatric brain tumors to their origins in the developing cerebellum
Okonechnikov, K., Joshi, P. K., Sepp, M., Leiss, K., Sarropoulos, I., Murat, F., Sill, M., Beck, P., Chan, K. C.-H., Korshunov, A., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad124 · Cited by 59
Self-citationReece, A. S., & Hulse, G. K. (2019) · Epigenetics · doi:10.1080/15592294.2019.1633868 · Cited by 51
Liquid biopsy for pediatric central nervous system tumors
Bonner, E. R., Bornhorst, M., Packer, R. J., & Nazarian, J. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0072-z · Cited by 50
Guillerman, R. P., Foulkes, W. D., & Priest, J. R. (2019) · Pediatric Radiology · doi:10.1007/s00247-019-04429-x · Cited by 48
Invited Review: DNA methylation‐based classification of paediatric brain tumours
Pérez, E., & Capper, D. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12598 · Cited by 53
Self-citationFang, F. Y., Rosenblum, J. S., Ho, W. S., & Heiss, J. D. (2022) · Cancers · doi:10.3390/cancers14092285 · Cited by 58
“Most WNT-derived tumors have a somatic CTNNB1 mutation, encoding B-catenin, and chromosomal variations like monosomy 6 [41,42].”
BackgroundWu, X., Zhang, L.-S., Toombs, J., Kuo, Y.-C., Piazza, J. T., Tuladhar, R., Barrett, Q., Fan, C.-W., Zhang, X., Walensky, L. D., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3616 · Cited by 47
Self-citationTan, I., Wojcinski, A., Rallapalli, H., Lao, Z., Sanghrajka, R. M., Stephen, D. N., Volkova, E., Korshunov, A., Remke, M., Taylor, M. D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717815115 · Cited by 51
Self-citationTargeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33
Tantravedi, S., Vesuna, F., Winnard, P. T., Martin, A. M., Lim, M. K., Eberhart, C. G., Berlinicke, C. A., Raabe, E. H., van Diest, P. J., & Raman, V. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.09.002 · Cited by 49
Slavc, I., Mayr, L., Stepien, N. M., Gojo, J., Lippolis, M. A., Azizi, A. A., Chocholous, M., Baumgartner, A., Hedrich, C., Holm, S., et al. (2022) · Cancers · doi:10.3390/cancers14205128 · Cited by 53
Self-citation
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.